| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 194 | 2023 | 4251 | 5.760 |
Why?
|
| Transplantation Chimera | 35 | 2021 | 613 | 4.000 |
Why?
|
| Transplantation Tolerance | 31 | 2023 | 617 | 3.810 |
Why?
|
| Graft Survival | 64 | 2021 | 3734 | 2.640 |
Why?
|
| Bone Marrow Transplantation | 43 | 2019 | 2764 | 2.520 |
Why?
|
| Graft Rejection | 98 | 2021 | 4398 | 2.480 |
Why?
|
| Liver Transplantation | 51 | 2017 | 2119 | 2.420 |
Why?
|
| Immunosuppressive Agents | 64 | 2021 | 4152 | 2.060 |
Why?
|
| Macaca fascicularis | 65 | 2019 | 915 | 1.900 |
Why?
|
| Immune Tolerance | 33 | 2019 | 2258 | 1.500 |
Why?
|
| Transplantation, Homologous | 79 | 2022 | 4777 | 1.340 |
Why?
|
| Histocompatibility Testing | 19 | 2019 | 741 | 1.330 |
Why?
|
| Antilymphocyte Serum | 29 | 2016 | 492 | 1.250 |
Why?
|
| Isoantibodies | 17 | 2021 | 679 | 1.190 |
Why?
|
| Antibodies, Monoclonal | 55 | 2015 | 9272 | 1.130 |
Why?
|
| Organ Transplantation | 12 | 2022 | 1140 | 1.090 |
Why?
|
| Chimerism | 11 | 2023 | 158 | 1.000 |
Why?
|
| Transplantation Conditioning | 24 | 2019 | 1599 | 0.990 |
Why?
|
| HLA Antigens | 21 | 2021 | 1382 | 0.910 |
Why?
|
| Kidney Failure, Chronic | 15 | 2019 | 2534 | 0.890 |
Why?
|
| Transplantation, Heterologous | 18 | 2017 | 2378 | 0.790 |
Why?
|
| Transplantation Immunology | 11 | 2015 | 546 | 0.740 |
Why?
|
| Living Donors | 7 | 2012 | 621 | 0.650 |
Why?
|
| Tissue Donors | 23 | 2015 | 2241 | 0.610 |
Why?
|
| CD40 Ligand | 6 | 2016 | 526 | 0.550 |
Why?
|
| Nobel Prize | 2 | 2006 | 49 | 0.550 |
Why?
|
| Transplantation | 3 | 2008 | 217 | 0.550 |
Why?
|
| T-Lymphocytes | 39 | 2015 | 10179 | 0.510 |
Why?
|
| Hepatitis C | 14 | 2008 | 1591 | 0.510 |
Why?
|
| Pancreas Transplantation | 7 | 1998 | 187 | 0.500 |
Why?
|
| Primates | 8 | 2023 | 545 | 0.490 |
Why?
|
| Cyclosporine | 16 | 2015 | 788 | 0.480 |
Why?
|
| Histocompatibility | 4 | 2021 | 330 | 0.480 |
Why?
|
| Muromonab-CD3 | 8 | 2000 | 96 | 0.450 |
Why?
|
| Kidney Diseases | 14 | 2014 | 2146 | 0.440 |
Why?
|
| Receptors, Tumor Necrosis Factor | 4 | 1997 | 595 | 0.440 |
Why?
|
| Sentinel Lymph Node Biopsy | 6 | 2015 | 710 | 0.430 |
Why?
|
| Bloodletting | 1 | 2011 | 23 | 0.400 |
Why?
|
| Cyclosporins | 11 | 1991 | 220 | 0.400 |
Why?
|
| Complement C4b | 9 | 2009 | 135 | 0.380 |
Why?
|
| Multiple Myeloma | 6 | 2019 | 5185 | 0.370 |
Why?
|
| Phlebotomy | 1 | 2011 | 141 | 0.370 |
Why?
|
| Blood Cell Count | 1 | 2011 | 403 | 0.360 |
Why?
|
| Receptors, Interleukin-2 | 8 | 1995 | 573 | 0.350 |
Why?
|
| Bile Duct Neoplasms | 2 | 2005 | 567 | 0.350 |
Why?
|
| Blood Chemical Analysis | 1 | 2011 | 440 | 0.340 |
Why?
|
| Hospital Charges | 1 | 2011 | 362 | 0.340 |
Why?
|
| Animals | 109 | 2023 | 168660 | 0.330 |
Why?
|
| Immunologic Memory | 8 | 2015 | 1347 | 0.320 |
Why?
|
| Whole-Body Irradiation | 11 | 2014 | 449 | 0.320 |
Why?
|
| Kidney | 31 | 2019 | 7185 | 0.310 |
Why?
|
| Altruism | 1 | 2009 | 204 | 0.300 |
Why?
|
| Melanoma | 14 | 2015 | 5508 | 0.300 |
Why?
|
| Liver Failure, Acute | 2 | 2012 | 165 | 0.300 |
Why?
|
| Awareness | 1 | 2011 | 639 | 0.290 |
Why?
|
| Postoperative Complications | 31 | 2019 | 15281 | 0.280 |
Why?
|
| Papio | 12 | 2017 | 656 | 0.280 |
Why?
|
| Blood Coagulation Factors | 4 | 2017 | 355 | 0.280 |
Why?
|
| Allergy and Immunology | 1 | 2008 | 169 | 0.270 |
Why?
|
| Interleukin-2 | 5 | 2015 | 1904 | 0.270 |
Why?
|
| Cell Adhesion Molecules | 7 | 1995 | 1602 | 0.270 |
Why?
|
| Cytomegalovirus Infections | 19 | 2017 | 820 | 0.270 |
Why?
|
| Models, Animal | 8 | 2017 | 2172 | 0.260 |
Why?
|
| Cystic Duct | 1 | 2005 | 19 | 0.260 |
Why?
|
| Humans | 226 | 2022 | 743811 | 0.250 |
Why?
|
| Antibodies, Heterophile | 7 | 1999 | 126 | 0.250 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 9 | 1989 | 906 | 0.250 |
Why?
|
| Tissue and Organ Procurement | 6 | 2015 | 896 | 0.250 |
Why?
|
| Tissue and Organ Harvesting | 2 | 2008 | 369 | 0.250 |
Why?
|
| Skin Neoplasms | 13 | 2015 | 5691 | 0.250 |
Why?
|
| Hospital Costs | 1 | 2011 | 985 | 0.250 |
Why?
|
| Liver Neoplasms | 7 | 2010 | 4251 | 0.240 |
Why?
|
| Killer Cells, Natural | 5 | 2018 | 2131 | 0.240 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2006 | 160 | 0.240 |
Why?
|
| Hyperoxaluria, Primary | 2 | 2013 | 22 | 0.230 |
Why?
|
| Lymph Nodes | 9 | 2015 | 3476 | 0.230 |
Why?
|
| Ethics, Medical | 4 | 2009 | 792 | 0.230 |
Why?
|
| Immunotoxins | 2 | 2012 | 179 | 0.220 |
Why?
|
| Lymph Node Excision | 3 | 2015 | 1262 | 0.220 |
Why?
|
| Carcinoma, Hepatocellular | 5 | 2010 | 2217 | 0.220 |
Why?
|
| Creatinine | 15 | 2012 | 1918 | 0.210 |
Why?
|
| Cholestasis | 2 | 2005 | 378 | 0.210 |
Why?
|
| Antibodies | 12 | 2022 | 2459 | 0.210 |
Why?
|
| Lymphopoiesis | 1 | 2002 | 135 | 0.210 |
Why?
|
| Islets of Langerhans Transplantation | 3 | 2016 | 745 | 0.210 |
Why?
|
| Lung Transplantation | 4 | 2015 | 1155 | 0.200 |
Why?
|
| Male | 125 | 2019 | 349776 | 0.200 |
Why?
|
| History, 20th Century | 5 | 2015 | 2736 | 0.200 |
Why?
|
| Antiviral Agents | 13 | 2017 | 2984 | 0.200 |
Why?
|
| T-Lymphocytes, Regulatory | 9 | 2019 | 2988 | 0.200 |
Why?
|
| Thrombophilia | 1 | 2004 | 305 | 0.190 |
Why?
|
| Portal Vein | 2 | 2013 | 437 | 0.190 |
Why?
|
| Middle Aged | 87 | 2019 | 213241 | 0.190 |
Why?
|
| Glomerulonephritis | 3 | 2002 | 372 | 0.190 |
Why?
|
| Postoperative Care | 4 | 2009 | 1485 | 0.190 |
Why?
|
| Immunologic Techniques | 2 | 1999 | 219 | 0.180 |
Why?
|
| Intraoperative Care | 2 | 2003 | 767 | 0.180 |
Why?
|
| Tacrolimus | 5 | 2004 | 743 | 0.180 |
Why?
|
| Hepatectomy | 1 | 2003 | 550 | 0.180 |
Why?
|
| Mycophenolic Acid | 5 | 2004 | 343 | 0.180 |
Why?
|
| Waiting Lists | 4 | 2015 | 692 | 0.180 |
Why?
|
| Survival Rate | 15 | 2017 | 12786 | 0.180 |
Why?
|
| Nephrectomy | 3 | 2012 | 1048 | 0.180 |
Why?
|
| Antibodies, Anti-Idiotypic | 5 | 1990 | 349 | 0.180 |
Why?
|
| Immunoconjugates | 2 | 2014 | 901 | 0.180 |
Why?
|
| Adult | 94 | 2019 | 213889 | 0.170 |
Why?
|
| Major Histocompatibility Complex | 7 | 2019 | 936 | 0.170 |
Why?
|
| Lymphocyte Depletion | 7 | 2010 | 608 | 0.170 |
Why?
|
| Hepatitis B, Chronic | 1 | 2003 | 392 | 0.170 |
Why?
|
| Time Factors | 39 | 2018 | 40038 | 0.170 |
Why?
|
| Interferon-alpha | 5 | 2004 | 895 | 0.170 |
Why?
|
| Viremia | 4 | 1998 | 736 | 0.160 |
Why?
|
| Cholestasis, Intrahepatic | 1 | 1998 | 68 | 0.160 |
Why?
|
| Splenectomy | 7 | 2010 | 394 | 0.160 |
Why?
|
| Venous Thrombosis | 2 | 2006 | 1240 | 0.160 |
Why?
|
| Health Expenditures | 1 | 2011 | 2348 | 0.160 |
Why?
|
| Immunoglobulin G | 12 | 2000 | 4561 | 0.160 |
Why?
|
| Chimera | 6 | 1999 | 484 | 0.150 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2023 | 5445 | 0.150 |
Why?
|
| Cardiolipins | 1 | 1997 | 88 | 0.150 |
Why?
|
| Treatment Outcome | 23 | 2021 | 63042 | 0.150 |
Why?
|
| Hematopoiesis | 2 | 2019 | 2073 | 0.150 |
Why?
|
| Thromboembolism | 2 | 2004 | 987 | 0.150 |
Why?
|
| Lymphocyte Transfusion | 1 | 1998 | 236 | 0.150 |
Why?
|
| Antibody Formation | 10 | 2002 | 1402 | 0.150 |
Why?
|
| Recombinant Fusion Proteins | 7 | 2013 | 3772 | 0.150 |
Why?
|
| Graft vs Host Reaction | 1 | 1997 | 104 | 0.150 |
Why?
|
| Flow Cytometry | 13 | 2015 | 5973 | 0.150 |
Why?
|
| Resource Allocation | 3 | 2015 | 341 | 0.140 |
Why?
|
| Female | 93 | 2019 | 380020 | 0.140 |
Why?
|
| Portacaval Shunt, Surgical | 1 | 1996 | 49 | 0.140 |
Why?
|
| Enzyme Inhibitors | 2 | 2010 | 3794 | 0.140 |
Why?
|
| Immunoglobulin M | 5 | 2000 | 1537 | 0.140 |
Why?
|
| Hepatic Artery | 1 | 1997 | 246 | 0.140 |
Why?
|
| History, 21st Century | 3 | 2015 | 1532 | 0.140 |
Why?
|
| Hepatitis, Chronic | 1 | 1996 | 52 | 0.140 |
Why?
|
| Swine | 13 | 2017 | 5909 | 0.140 |
Why?
|
| Ganciclovir | 4 | 2000 | 258 | 0.140 |
Why?
|
| Complement Activation | 5 | 2001 | 453 | 0.130 |
Why?
|
| Histocompatibility Antigens | 1 | 2017 | 471 | 0.130 |
Why?
|
| Receptors, Fc | 2 | 1989 | 541 | 0.130 |
Why?
|
| Complement C4 | 6 | 2002 | 257 | 0.130 |
Why?
|
| Vascular Diseases | 2 | 2022 | 1161 | 0.130 |
Why?
|
| Lymphocyte Culture Test, Mixed | 4 | 2006 | 518 | 0.130 |
Why?
|
| Endothelium | 2 | 2018 | 777 | 0.130 |
Why?
|
| B-Cell Activating Factor | 1 | 2015 | 119 | 0.130 |
Why?
|
| Peptide Fragments | 9 | 2009 | 5096 | 0.130 |
Why?
|
| Follow-Up Studies | 18 | 2019 | 39001 | 0.130 |
Why?
|
| Intercellular Adhesion Molecule-1 | 7 | 1995 | 1159 | 0.130 |
Why?
|
| Patient Selection | 6 | 2009 | 4210 | 0.120 |
Why?
|
| Lymphedema | 2 | 2000 | 534 | 0.120 |
Why?
|
| Adenoma | 2 | 2005 | 2173 | 0.120 |
Why?
|
| Gene Expression Profiling | 4 | 2018 | 9440 | 0.120 |
Why?
|
| Haplorhini | 5 | 2009 | 548 | 0.120 |
Why?
|
| General Surgery | 1 | 2006 | 1636 | 0.120 |
Why?
|
| Death | 2 | 2010 | 678 | 0.120 |
Why?
|
| Leukocyte Count | 9 | 2011 | 1588 | 0.120 |
Why?
|
| Acute Disease | 12 | 2003 | 7150 | 0.120 |
Why?
|
| Guanidines | 4 | 1999 | 193 | 0.120 |
Why?
|
| Registries | 3 | 2015 | 8090 | 0.120 |
Why?
|
| Cadaver | 7 | 2009 | 1335 | 0.120 |
Why?
|
| Embolization, Therapeutic | 2 | 2013 | 1392 | 0.120 |
Why?
|
| Nephrotic Syndrome | 1 | 1997 | 389 | 0.120 |
Why?
|
| Tissue Survival | 1 | 2013 | 118 | 0.110 |
Why?
|
| Health Care Rationing | 1 | 1996 | 437 | 0.110 |
Why?
|
| Hand-Assisted Laparoscopy | 1 | 2012 | 16 | 0.110 |
Why?
|
| Antigens, Differentiation | 3 | 1999 | 927 | 0.110 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2010 | 648 | 0.110 |
Why?
|
| Thymus Gland | 5 | 2007 | 1266 | 0.110 |
Why?
|
| ABO Blood-Group System | 4 | 2006 | 367 | 0.110 |
Why?
|
| Ribavirin | 3 | 2003 | 394 | 0.110 |
Why?
|
| Nevus | 1 | 2014 | 204 | 0.110 |
Why?
|
| Ureterostomy | 1 | 2012 | 17 | 0.110 |
Why?
|
| Drug Therapy, Combination | 9 | 2018 | 6487 | 0.110 |
Why?
|
| Cystostomy | 1 | 2012 | 26 | 0.110 |
Why?
|
| Chronic Disease | 12 | 2017 | 9139 | 0.110 |
Why?
|
| Hypertension, Malignant | 1 | 2012 | 19 | 0.100 |
Why?
|
| Myeloablative Agonists | 1 | 2013 | 218 | 0.100 |
Why?
|
| Prognosis | 13 | 2015 | 29052 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 8 | 2009 | 3874 | 0.100 |
Why?
|
| Membrane Glycoproteins | 2 | 2000 | 3769 | 0.100 |
Why?
|
| Hepacivirus | 4 | 2008 | 1378 | 0.100 |
Why?
|
| Azathioprine | 5 | 1994 | 354 | 0.100 |
Why?
|
| Capillary Leak Syndrome | 1 | 2011 | 31 | 0.100 |
Why?
|
| Retrospective Studies | 33 | 2019 | 77410 | 0.100 |
Why?
|
| Diphtheria Toxin | 1 | 2012 | 255 | 0.100 |
Why?
|
| Defensive Medicine | 1 | 2011 | 48 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2018 | 4477 | 0.090 |
Why?
|
| Galactosyltransferases | 1 | 2012 | 264 | 0.090 |
Why?
|
| Ureter | 2 | 2012 | 375 | 0.090 |
Why?
|
| Steroids | 4 | 2001 | 930 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 1 | 7 | 1998 | 3338 | 0.090 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2014 | 604 | 0.090 |
Why?
|
| Lymphatic Metastasis | 6 | 2015 | 2924 | 0.090 |
Why?
|
| Thrombocytopenia | 2 | 2016 | 1178 | 0.090 |
Why?
|
| Mesentery | 1 | 2011 | 205 | 0.090 |
Why?
|
| Antibody Specificity | 6 | 2005 | 1095 | 0.090 |
Why?
|
| Liver Cirrhosis | 2 | 2008 | 1859 | 0.090 |
Why?
|
| Horses | 3 | 2015 | 304 | 0.090 |
Why?
|
| Opportunistic Infections | 2 | 2008 | 389 | 0.090 |
Why?
|
| B-Lymphocytes | 6 | 2015 | 4665 | 0.090 |
Why?
|
| Diabetes Mellitus | 4 | 2016 | 5752 | 0.090 |
Why?
|
| Biopsy | 17 | 2008 | 6750 | 0.090 |
Why?
|
| Stem Cell Factor | 1 | 2010 | 219 | 0.090 |
Why?
|
| Heart Transplantation | 5 | 2002 | 3113 | 0.090 |
Why?
|
| Syndrome | 4 | 2005 | 3249 | 0.090 |
Why?
|
| Carcinoid Tumor | 1 | 2011 | 235 | 0.090 |
Why?
|
| Sirolimus | 1 | 2016 | 1565 | 0.080 |
Why?
|
| Graft vs Host Disease | 2 | 2017 | 2958 | 0.080 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2010 | 227 | 0.080 |
Why?
|
| Pathology, Clinical | 1 | 2012 | 368 | 0.080 |
Why?
|
| Acyclovir | 3 | 2000 | 272 | 0.080 |
Why?
|
| Cytotoxicity, Immunologic | 9 | 2000 | 1369 | 0.080 |
Why?
|
| Hepatitis B | 1 | 1994 | 693 | 0.080 |
Why?
|
| Cost Control | 1 | 2011 | 624 | 0.080 |
Why?
|
| Lymphocele | 1 | 2008 | 16 | 0.080 |
Why?
|
| Disaccharides | 2 | 2000 | 171 | 0.080 |
Why?
|
| Vena Cava, Inferior | 2 | 2006 | 439 | 0.080 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2010 | 430 | 0.080 |
Why?
|
| Hepatitis, Viral, Human | 2 | 1988 | 138 | 0.080 |
Why?
|
| Prednisone | 5 | 2000 | 1574 | 0.080 |
Why?
|
| Aspergillus | 1 | 2008 | 85 | 0.080 |
Why?
|
| Dermatomycoses | 1 | 2008 | 45 | 0.080 |
Why?
|
| Kidney Function Tests | 4 | 2015 | 684 | 0.080 |
Why?
|
| RNA | 1 | 2018 | 2748 | 0.080 |
Why?
|
| Physicians | 1 | 2006 | 4569 | 0.080 |
Why?
|
| Glomerular Filtration Rate | 4 | 2015 | 2167 | 0.080 |
Why?
|
| Reoperation | 5 | 2012 | 4200 | 0.080 |
Why?
|
| Tumor Virus Infections | 2 | 2001 | 454 | 0.080 |
Why?
|
| Unnecessary Procedures | 1 | 2011 | 432 | 0.070 |
Why?
|
| Hematologic Neoplasms | 1 | 2019 | 1832 | 0.070 |
Why?
|
| Thrombosis | 2 | 1999 | 2968 | 0.070 |
Why?
|
| T-Lymphocytes, Cytotoxic | 4 | 1993 | 1821 | 0.070 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2012 | 738 | 0.070 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2008 | 107 | 0.070 |
Why?
|
| Brain Death | 1 | 2010 | 348 | 0.070 |
Why?
|
| Lymphocytes | 6 | 1998 | 2615 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 1997 | 4422 | 0.070 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 1994 | 2540 | 0.070 |
Why?
|
| Oxygen Consumption | 1 | 2013 | 1869 | 0.070 |
Why?
|
| RNA, Messenger | 3 | 2019 | 13028 | 0.070 |
Why?
|
| Lymphoma, B-Cell | 1 | 1993 | 931 | 0.070 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2012 | 4386 | 0.070 |
Why?
|
| Aged | 30 | 2019 | 163178 | 0.070 |
Why?
|
| Actuarial Analysis | 2 | 1996 | 378 | 0.070 |
Why?
|
| Forecasting | 2 | 2011 | 2950 | 0.070 |
Why?
|
| Boston | 6 | 2012 | 9310 | 0.070 |
Why?
|
| Aspergillosis | 1 | 2008 | 235 | 0.070 |
Why?
|
| Lung Diseases | 2 | 2015 | 1887 | 0.070 |
Why?
|
| Nephritis, Hereditary | 1 | 2006 | 88 | 0.070 |
Why?
|
| Cytomegalovirus | 7 | 2000 | 733 | 0.070 |
Why?
|
| Clinical Trials as Topic | 11 | 2017 | 7908 | 0.070 |
Why?
|
| France | 1 | 2006 | 517 | 0.070 |
Why?
|
| Recombinant Proteins | 5 | 2003 | 6620 | 0.060 |
Why?
|
| Hemorrhage | 2 | 2016 | 3458 | 0.060 |
Why?
|
| Kidney Glomerulus | 5 | 1998 | 697 | 0.060 |
Why?
|
| Plasmacytoma | 1 | 2006 | 183 | 0.060 |
Why?
|
| RNA, Viral | 2 | 2008 | 2901 | 0.060 |
Why?
|
| Hemophilia A | 1 | 1988 | 351 | 0.060 |
Why?
|
| Peritoneal Neoplasms | 1 | 2011 | 665 | 0.060 |
Why?
|
| Haplotypes | 1 | 2011 | 2779 | 0.060 |
Why?
|
| Hepatoblastoma | 1 | 2005 | 87 | 0.060 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2005 | 54 | 0.060 |
Why?
|
| Ketorolac Tromethamine | 1 | 2004 | 21 | 0.060 |
Why?
|
| Neoplasm Staging | 7 | 2012 | 11036 | 0.060 |
Why?
|
| Swine, Miniature | 3 | 2016 | 961 | 0.060 |
Why?
|
| United States | 8 | 2015 | 69859 | 0.060 |
Why?
|
| Alprostadil | 1 | 2004 | 89 | 0.060 |
Why?
|
| Immunity, Cellular | 6 | 2001 | 1608 | 0.060 |
Why?
|
| Mice | 14 | 2017 | 81154 | 0.060 |
Why?
|
| Incidence | 7 | 2015 | 20948 | 0.060 |
Why?
|
| Lymphatic Vessels | 1 | 2008 | 353 | 0.060 |
Why?
|
| Blood Vessels | 2 | 1999 | 1124 | 0.060 |
Why?
|
| Reproductive Behavior | 1 | 2003 | 29 | 0.060 |
Why?
|
| History, 19th Century | 1 | 2006 | 720 | 0.060 |
Why?
|
| Australia | 1 | 2006 | 1167 | 0.060 |
Why?
|
| Cryoglobulinemia | 2 | 2002 | 87 | 0.060 |
Why?
|
| Drug Costs | 1 | 2011 | 1105 | 0.060 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 1993 | 1377 | 0.060 |
Why?
|
| Immunoglobulin Idiotypes | 3 | 1989 | 201 | 0.060 |
Why?
|
| Neutropenia | 1 | 2008 | 895 | 0.060 |
Why?
|
| Islets of Langerhans | 3 | 2010 | 1350 | 0.060 |
Why?
|
| Intestines | 2 | 2011 | 1923 | 0.060 |
Why?
|
| Length of Stay | 4 | 2003 | 6311 | 0.060 |
Why?
|
| Genes, bcl-2 | 1 | 2023 | 122 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2006 | 1836 | 0.050 |
Why?
|
| Monitoring, Physiologic | 3 | 2006 | 1738 | 0.050 |
Why?
|
| Porphyria, Hepatoerythropoietic | 1 | 2002 | 8 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2008 | 2241 | 0.050 |
Why?
|
| Hemin | 1 | 2002 | 50 | 0.050 |
Why?
|
| Complement C3b | 2 | 1999 | 106 | 0.050 |
Why?
|
| Insulin Resistance | 2 | 2008 | 3863 | 0.050 |
Why?
|
| Skin Transplantation | 3 | 2009 | 1074 | 0.050 |
Why?
|
| Food Hypersensitivity | 1 | 2009 | 622 | 0.050 |
Why?
|
| Delayed Graft Function | 2 | 2012 | 48 | 0.050 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2008 | 646 | 0.050 |
Why?
|
| Menstruation | 1 | 2003 | 302 | 0.050 |
Why?
|
| Combined Modality Therapy | 5 | 2013 | 8637 | 0.050 |
Why?
|
| Dose-Response Relationship, Immunologic | 4 | 2006 | 370 | 0.050 |
Why?
|
| Prospective Studies | 14 | 2008 | 53250 | 0.050 |
Why?
|
| Receptors, Immunologic | 2 | 1988 | 1423 | 0.050 |
Why?
|
| Diabetic Nephropathies | 2 | 1988 | 984 | 0.050 |
Why?
|
| Contraception Behavior | 1 | 2003 | 185 | 0.050 |
Why?
|
| Animals, Genetically Modified | 2 | 2017 | 1552 | 0.050 |
Why?
|
| Fallopian Tube Diseases | 1 | 2001 | 62 | 0.050 |
Why?
|
| Survival Analysis | 4 | 2004 | 10251 | 0.050 |
Why?
|
| BK Virus | 1 | 2001 | 129 | 0.050 |
Why?
|
| Pseudomonas Infections | 2 | 2001 | 608 | 0.050 |
Why?
|
| Complement System Proteins | 2 | 2001 | 796 | 0.050 |
Why?
|
| Patient Compliance | 3 | 2009 | 2683 | 0.050 |
Why?
|
| Transplantation, Autologous | 3 | 2015 | 2123 | 0.050 |
Why?
|
| Adaptation, Physiological | 1 | 2007 | 1311 | 0.050 |
Why?
|
| Acute Kidney Injury | 2 | 2011 | 1968 | 0.050 |
Why?
|
| Leukopenia | 2 | 2000 | 213 | 0.050 |
Why?
|
| Ovarian Diseases | 1 | 2001 | 139 | 0.050 |
Why?
|
| Antigens, CD | 3 | 1999 | 4026 | 0.050 |
Why?
|
| Decision Support Techniques | 1 | 2010 | 1956 | 0.050 |
Why?
|
| Growth Substances | 2 | 1999 | 784 | 0.040 |
Why?
|
| Isoantigens | 3 | 2011 | 567 | 0.040 |
Why?
|
| Adolescent | 16 | 2015 | 85729 | 0.040 |
Why?
|
| Cholangiocarcinoma | 1 | 2005 | 516 | 0.040 |
Why?
|
| Polyomavirus Infections | 1 | 2001 | 200 | 0.040 |
Why?
|
| Esophageal Diseases | 1 | 2000 | 167 | 0.040 |
Why?
|
| Drug Combinations | 2 | 2004 | 1958 | 0.040 |
Why?
|
| Dactinomycin | 2 | 1998 | 318 | 0.040 |
Why?
|
| Premenopause | 1 | 2003 | 1033 | 0.040 |
Why?
|
| Recurrence | 6 | 2003 | 8337 | 0.040 |
Why?
|
| Epitopes | 4 | 1999 | 2570 | 0.040 |
Why?
|
| Antibodies, Anticardiolipin | 1 | 1999 | 62 | 0.040 |
Why?
|
| GATA3 Transcription Factor | 1 | 2019 | 157 | 0.040 |
Why?
|
| Renal Circulation | 1 | 1999 | 334 | 0.040 |
Why?
|
| Ulcer | 1 | 2000 | 209 | 0.040 |
Why?
|
| Cell Separation | 3 | 2001 | 1750 | 0.040 |
Why?
|
| Complement Membrane Attack Complex | 1 | 1999 | 112 | 0.040 |
Why?
|
| Bone Marrow Cells | 2 | 2013 | 2509 | 0.040 |
Why?
|
| End Stage Liver Disease | 2 | 2015 | 314 | 0.040 |
Why?
|
| Hepatitis C Antibodies | 1 | 1998 | 145 | 0.040 |
Why?
|
| Cells, Cultured | 6 | 2017 | 19232 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 2 | 2019 | 1613 | 0.040 |
Why?
|
| Polyomavirus | 1 | 1999 | 249 | 0.040 |
Why?
|
| Rabbits | 2 | 2016 | 4894 | 0.040 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 1998 | 188 | 0.040 |
Why?
|
| Massage | 1 | 1998 | 85 | 0.040 |
Why?
|
| Plasma Exchange | 1 | 1998 | 152 | 0.040 |
Why?
|
| Abscess | 1 | 2001 | 607 | 0.040 |
Why?
|
| Renal Artery | 2 | 1999 | 399 | 0.040 |
Why?
|
| Methylprednisolone | 3 | 2001 | 387 | 0.040 |
Why?
|
| Child | 11 | 2015 | 77637 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 12066 | 0.040 |
Why?
|
| Chromatography, Affinity | 1 | 1998 | 549 | 0.040 |
Why?
|
| Disease Models, Animal | 5 | 2017 | 18027 | 0.040 |
Why?
|
| Bioethics | 1 | 1998 | 116 | 0.040 |
Why?
|
| Pancytopenia | 1 | 1997 | 104 | 0.040 |
Why?
|
| Heparin | 1 | 2004 | 1637 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2010 | 9239 | 0.040 |
Why?
|
| Risk Assessment | 5 | 2015 | 23327 | 0.040 |
Why?
|
| Hospitals, General | 1 | 2001 | 749 | 0.040 |
Why?
|
| Neoplasm Metastasis | 2 | 2005 | 4848 | 0.040 |
Why?
|
| False Negative Reactions | 2 | 2012 | 588 | 0.030 |
Why?
|
| Lymphocyte Activation | 5 | 1999 | 5524 | 0.030 |
Why?
|
| Bandages | 1 | 1998 | 266 | 0.030 |
Why?
|
| Constriction | 1 | 1996 | 181 | 0.030 |
Why?
|
| Urinary Tract Infections | 4 | 1992 | 788 | 0.030 |
Why?
|
| Immunization | 3 | 2001 | 1255 | 0.030 |
Why?
|
| Hodgkin Disease | 1 | 1984 | 1415 | 0.030 |
Why?
|
| Cytotoxicity Tests, Immunologic | 2 | 1994 | 329 | 0.030 |
Why?
|
| Technetium Tc 99m Pentetate | 1 | 1995 | 68 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 1999 | 1475 | 0.030 |
Why?
|
| Social Values | 1 | 1996 | 224 | 0.030 |
Why?
|
| Hepatitis C, Chronic | 1 | 2004 | 1029 | 0.030 |
Why?
|
| Kidney Tubular Necrosis, Acute | 2 | 2011 | 66 | 0.030 |
Why?
|
| Enalapril | 1 | 1997 | 327 | 0.030 |
Why?
|
| Antigens, Surface | 5 | 1987 | 1663 | 0.030 |
Why?
|
| Bone Marrow | 2 | 2019 | 2951 | 0.030 |
Why?
|
| Young Adult | 4 | 2015 | 56392 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2012 | 6539 | 0.030 |
Why?
|
| Thrombophlebitis | 1 | 1996 | 309 | 0.030 |
Why?
|
| Dimerization | 1 | 1997 | 894 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1998 | 902 | 0.030 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2001 | 1115 | 0.030 |
Why?
|
| Fatal Outcome | 3 | 2009 | 1851 | 0.030 |
Why?
|
| Hepatitis B Surface Antigens | 2 | 1994 | 304 | 0.030 |
Why?
|
| Hepatitis Delta Virus | 1 | 1994 | 18 | 0.030 |
Why?
|
| Liver Function Tests | 4 | 2002 | 529 | 0.030 |
Why?
|
| Renal Dialysis | 3 | 2002 | 1783 | 0.030 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 1998 | 357 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 2 | 2019 | 2006 | 0.030 |
Why?
|
| Proteinuria | 1 | 1997 | 658 | 0.030 |
Why?
|
| Quality of Life | 2 | 1996 | 12788 | 0.030 |
Why?
|
| Biphenyl Compounds | 1 | 1998 | 913 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2019 | 1200 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2007 | 3207 | 0.030 |
Why?
|
| Rodentia | 1 | 1995 | 261 | 0.030 |
Why?
|
| Demography | 1 | 1999 | 1653 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2015 | 667 | 0.030 |
Why?
|
| Binding Sites, Antibody | 1 | 1994 | 349 | 0.030 |
Why?
|
| Gene Transfer Techniques | 1 | 1999 | 1224 | 0.030 |
Why?
|
| Anemia, Sickle Cell | 1 | 2002 | 1020 | 0.030 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2015 | 225 | 0.030 |
Why?
|
| Foot | 1 | 1997 | 527 | 0.030 |
Why?
|
| Microscopy, Electron | 4 | 1999 | 2646 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2005 | 2267 | 0.030 |
Why?
|
| Oxalates | 1 | 2013 | 105 | 0.030 |
Why?
|
| Solubility | 1 | 1995 | 1088 | 0.030 |
Why?
|
| Perfusion | 2 | 2013 | 1359 | 0.030 |
Why?
|
| Hepatic Encephalopathy | 2 | 2012 | 139 | 0.030 |
Why?
|
| Monitoring, Immunologic | 1 | 1993 | 99 | 0.030 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 1995 | 278 | 0.030 |
Why?
|
| Th1 Cells | 1 | 2018 | 1057 | 0.030 |
Why?
|
| Drug Resistance | 2 | 2001 | 1606 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2002 | 1854 | 0.030 |
Why?
|
| Prednisolone | 2 | 2004 | 334 | 0.030 |
Why?
|
| Papio hamadryas | 1 | 2012 | 29 | 0.030 |
Why?
|
| Immunoglobulin Isotypes | 2 | 1998 | 158 | 0.030 |
Why?
|
| Self Care | 1 | 1998 | 786 | 0.030 |
Why?
|
| Postmenopause | 1 | 2001 | 2458 | 0.030 |
Why?
|
| Geography | 1 | 2015 | 669 | 0.030 |
Why?
|
| Cytokines | 3 | 2015 | 7324 | 0.030 |
Why?
|
| Adenoma, Bile Duct | 1 | 1992 | 30 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 3 | 2009 | 2692 | 0.030 |
Why?
|
| Spleen | 1 | 1998 | 2359 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 1999 | 3503 | 0.030 |
Why?
|
| Genotype | 2 | 2019 | 12944 | 0.030 |
Why?
|
| Child, Preschool | 6 | 2005 | 40964 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2008 | 3308 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2012 | 10940 | 0.030 |
Why?
|
| Cardiovascular Diseases | 3 | 2004 | 15142 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2002 | 2503 | 0.030 |
Why?
|
| DNA, Viral | 2 | 1999 | 2226 | 0.030 |
Why?
|
| Antibodies, Viral | 2 | 1994 | 3175 | 0.030 |
Why?
|
| Hand | 1 | 1997 | 884 | 0.030 |
Why?
|
| Radiation Chimera | 1 | 2011 | 223 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2019 | 8316 | 0.020 |
Why?
|
| Survival | 1 | 1992 | 163 | 0.020 |
Why?
|
| Interleukin-15 | 1 | 2012 | 184 | 0.020 |
Why?
|
| Cell Line | 4 | 2009 | 15993 | 0.020 |
Why?
|
| Erythrocyte Transfusion | 1 | 1996 | 565 | 0.020 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2004 | 3070 | 0.020 |
Why?
|
| Learning Curve | 1 | 2012 | 208 | 0.020 |
Why?
|
| Exercise Therapy | 1 | 1998 | 904 | 0.020 |
Why?
|
| Cancer Vaccines | 1 | 1998 | 1023 | 0.020 |
Why?
|
| Immunohistochemistry | 4 | 2011 | 11360 | 0.020 |
Why?
|
| Kidney Tubules | 3 | 2001 | 488 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2011 | 5787 | 0.020 |
Why?
|
| Risk Factors | 7 | 2015 | 72252 | 0.020 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 1997 | 1516 | 0.020 |
Why?
|
| Hemostasis, Surgical | 1 | 2011 | 128 | 0.020 |
Why?
|
| Administration, Oral | 3 | 2000 | 3912 | 0.020 |
Why?
|
| Rupture, Spontaneous | 1 | 2011 | 354 | 0.020 |
Why?
|
| Ciprofloxacin | 1 | 1992 | 314 | 0.020 |
Why?
|
| Massachusetts | 3 | 2015 | 8660 | 0.020 |
Why?
|
| Liver Diseases | 1 | 1999 | 1253 | 0.020 |
Why?
|
| Medical Records | 1 | 1996 | 1412 | 0.020 |
Why?
|
| Leg Dermatoses | 1 | 1989 | 20 | 0.020 |
Why?
|
| Laparoscopy | 3 | 2009 | 2148 | 0.020 |
Why?
|
| Leukapheresis | 1 | 2010 | 131 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2015 | 2008 | 0.020 |
Why?
|
| Aging | 1 | 2008 | 8655 | 0.020 |
Why?
|
| Biopsy, Needle | 3 | 2005 | 1639 | 0.020 |
Why?
|
| Intracranial Pressure | 1 | 2012 | 326 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 1989 | 380 | 0.020 |
Why?
|
| Intracranial Hypertension | 1 | 2012 | 186 | 0.020 |
Why?
|
| ROC Curve | 1 | 2017 | 3527 | 0.020 |
Why?
|
| Fluconazole | 1 | 1989 | 146 | 0.020 |
Why?
|
| Gene Knockout Techniques | 1 | 2012 | 807 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2010 | 964 | 0.020 |
Why?
|
| Cattle | 1 | 2015 | 3917 | 0.020 |
Why?
|
| Mycobacterium Infections | 1 | 1989 | 118 | 0.020 |
Why?
|
| Cholesterol | 2 | 2004 | 2922 | 0.020 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 1991 | 482 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 13691 | 0.020 |
Why?
|
| bcl-X Protein | 1 | 2010 | 411 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2004 | 4599 | 0.020 |
Why?
|
| Sex Distribution | 2 | 2005 | 2298 | 0.020 |
Why?
|
| Hemodynamics | 1 | 1999 | 4197 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 1996 | 1411 | 0.020 |
Why?
|
| Aged, 80 and over | 6 | 2015 | 57744 | 0.020 |
Why?
|
| Blood Loss, Surgical | 1 | 2012 | 660 | 0.020 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2010 | 272 | 0.020 |
Why?
|
| Macaca | 1 | 1990 | 439 | 0.020 |
Why?
|
| Age Factors | 2 | 1996 | 18355 | 0.020 |
Why?
|
| Blood Pressure | 3 | 2004 | 8551 | 0.020 |
Why?
|
| Interferons | 2 | 2004 | 706 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 1999 | 6170 | 0.020 |
Why?
|
| Fibrinogen | 2 | 2004 | 894 | 0.020 |
Why?
|
| Endoscopy, Digestive System | 1 | 2011 | 345 | 0.020 |
Why?
|
| Hypothermia, Induced | 1 | 2013 | 752 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 2 | 2003 | 418 | 0.020 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 1999 | 1354 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 1993 | 1758 | 0.020 |
Why?
|
| Communicable Diseases | 1 | 1996 | 880 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2011 | 1342 | 0.020 |
Why?
|
| Postoperative Period | 2 | 2004 | 1841 | 0.020 |
Why?
|
| Injections, Intravenous | 2 | 2000 | 1422 | 0.020 |
Why?
|
| Postoperative Hemorrhage | 1 | 2011 | 409 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2009 | 411 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2008 | 170 | 0.020 |
Why?
|
| Granuloma | 1 | 1989 | 319 | 0.020 |
Why?
|
| Inflammation | 2 | 2015 | 10629 | 0.020 |
Why?
|
| Personality Assessment | 1 | 2009 | 647 | 0.020 |
Why?
|
| Papillomavirus Infections | 1 | 1999 | 1587 | 0.020 |
Why?
|
| Intestinal Obstruction | 1 | 2011 | 424 | 0.020 |
Why?
|
| Viral Load | 2 | 2008 | 3300 | 0.020 |
Why?
|
| Capillaries | 2 | 2001 | 773 | 0.020 |
Why?
|
| Random Allocation | 3 | 1987 | 2429 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2002 | 3142 | 0.020 |
Why?
|
| Safety | 2 | 2003 | 1184 | 0.020 |
Why?
|
| BCG Vaccine | 1 | 1989 | 369 | 0.020 |
Why?
|
| Phenotype | 4 | 2017 | 16361 | 0.020 |
Why?
|
| Nucleoside Deaminases | 1 | 1986 | 58 | 0.020 |
Why?
|
| Granzymes | 1 | 2008 | 271 | 0.020 |
Why?
|
| Cause of Death | 2 | 2003 | 3580 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2011 | 1880 | 0.020 |
Why?
|
| Infant | 3 | 1999 | 35122 | 0.020 |
Why?
|
| Hyponatremia | 1 | 1989 | 297 | 0.020 |
Why?
|
| Mycoses | 1 | 1989 | 376 | 0.020 |
Why?
|
| Receptors, IgG | 1 | 1989 | 581 | 0.020 |
Why?
|
| Sick Role | 1 | 1987 | 237 | 0.020 |
Why?
|
| Diagnosis, Differential | 5 | 2008 | 12954 | 0.020 |
Why?
|
| Factor VIII | 1 | 1988 | 347 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2012 | 1301 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 1990 | 2327 | 0.020 |
Why?
|
| Diagnosis-Related Groups | 1 | 2007 | 455 | 0.020 |
Why?
|
| Blood Group Incompatibility | 1 | 2006 | 146 | 0.020 |
Why?
|
| Reference Values | 2 | 2005 | 4974 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 2 | 2010 | 6380 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2002 | 4260 | 0.020 |
Why?
|
| beta Catenin | 1 | 2010 | 1060 | 0.020 |
Why?
|
| Monitoring, Intraoperative | 1 | 2012 | 957 | 0.020 |
Why?
|
| Viral Hepatitis Vaccines | 1 | 1985 | 80 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2013 | 3205 | 0.020 |
Why?
|
| Psychophysiologic Disorders | 1 | 1987 | 228 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2011 | 2649 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 1999 | 18107 | 0.020 |
Why?
|
| Disease Progression | 2 | 2015 | 13273 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2009 | 1460 | 0.020 |
Why?
|
| Adoptive Transfer | 1 | 2007 | 844 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 1990 | 1680 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2004 | 12243 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2006 | 793 | 0.010 |
Why?
|
| Adenosine Deaminase | 1 | 1986 | 241 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 3 | 1984 | 985 | 0.010 |
Why?
|
| Immune System | 1 | 2009 | 807 | 0.010 |
Why?
|
| Angiography | 1 | 2009 | 1638 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 1990 | 9944 | 0.010 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2011 | 1131 | 0.010 |
Why?
|
| Triglycerides | 1 | 1991 | 2453 | 0.010 |
Why?
|
| Pulmonary Embolism | 1 | 1996 | 2375 | 0.010 |
Why?
|
| Stroke Volume | 1 | 1996 | 5002 | 0.010 |
Why?
|
| Glucocorticoids | 2 | 2003 | 2107 | 0.010 |
Why?
|
| Signal Transduction | 2 | 2011 | 23398 | 0.010 |
Why?
|
| Interferon Type I | 2 | 1983 | 541 | 0.010 |
Why?
|
| Sulfamethoxazole | 1 | 1982 | 53 | 0.010 |
Why?
|
| Drainage | 1 | 2008 | 1142 | 0.010 |
Why?
|
| Siblings | 1 | 2006 | 853 | 0.010 |
Why?
|
| Pancreas | 1 | 1989 | 1686 | 0.010 |
Why?
|
| Trimethoprim | 1 | 1982 | 91 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2013 | 8300 | 0.010 |
Why?
|
| Anaphylaxis | 1 | 2009 | 746 | 0.010 |
Why?
|
| Rosette Formation | 1 | 1981 | 153 | 0.010 |
Why?
|
| Complement C5b | 1 | 2001 | 9 | 0.010 |
Why?
|
| Base Sequence | 1 | 1993 | 12798 | 0.010 |
Why?
|
| Pregnancy | 1 | 2003 | 29140 | 0.010 |
Why?
|
| Peritoneal Dialysis | 1 | 2002 | 147 | 0.010 |
Why?
|
| Herpesviridae Infections | 1 | 1983 | 277 | 0.010 |
Why?
|
| Neutrophils | 2 | 2008 | 3718 | 0.010 |
Why?
|
| Complement C5 | 1 | 2001 | 112 | 0.010 |
Why?
|
| Rats | 2 | 2013 | 24250 | 0.010 |
Why?
|
| Homocysteine | 1 | 2004 | 647 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2017 | 10477 | 0.010 |
Why?
|
| Decision Making | 1 | 2015 | 3887 | 0.010 |
Why?
|
| Family Planning Services | 1 | 2003 | 263 | 0.010 |
Why?
|
| Blood Glucose | 2 | 2001 | 6259 | 0.010 |
Why?
|
| Extremities | 1 | 2006 | 867 | 0.010 |
Why?
|
| Cell Survival | 1 | 2010 | 5881 | 0.010 |
Why?
|
| Colonoscopy | 1 | 2008 | 1367 | 0.010 |
Why?
|
| Monocytes | 1 | 1989 | 2593 | 0.010 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 1999 | 66 | 0.010 |
Why?
|
| Probability | 1 | 2005 | 2505 | 0.010 |
Why?
|
| Patient Readmission | 1 | 1994 | 3117 | 0.010 |
Why?
|
| Herpes Simplex | 2 | 1983 | 470 | 0.010 |
Why?
|
| Hepatitis | 1 | 1981 | 227 | 0.010 |
Why?
|
| C-Peptide | 1 | 2001 | 420 | 0.010 |
Why?
|
| Cell Movement | 1 | 1992 | 5216 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 2883 | 0.010 |
Why?
|
| Complement C3 Convertase, Alternative Pathway | 1 | 1999 | 7 | 0.010 |
Why?
|
| Cytological Techniques | 1 | 1981 | 219 | 0.010 |
Why?
|
| Age Distribution | 1 | 2005 | 2899 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1987 | 4931 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 13980 | 0.010 |
Why?
|
| Ureteral Diseases | 1 | 1999 | 60 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2010 | 8436 | 0.010 |
Why?
|
| Antigens, Viral, Tumor | 1 | 1999 | 156 | 0.010 |
Why?
|
| Alcoholism | 1 | 2009 | 1907 | 0.010 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 1998 | 112 | 0.010 |
Why?
|
| Brain Injuries | 1 | 2010 | 2029 | 0.010 |
Why?
|
| Uric Acid | 1 | 2004 | 765 | 0.010 |
Why?
|
| Macaca mulatta | 2 | 1995 | 2375 | 0.010 |
Why?
|
| Immunosorbent Techniques | 1 | 1998 | 184 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 2010 | 2134 | 0.010 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 1999 | 110 | 0.010 |
Why?
|
| Models, Biological | 1 | 1995 | 9582 | 0.010 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2006 | 1837 | 0.010 |
Why?
|
| Disease-Free Survival | 2 | 2000 | 6895 | 0.010 |
Why?
|
| Antibodies, Neoplasm | 1 | 1999 | 286 | 0.010 |
Why?
|
| Enteritis | 1 | 1999 | 165 | 0.010 |
Why?
|
| Nephritis, Interstitial | 1 | 1999 | 154 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 1990 | 4459 | 0.010 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1998 | 484 | 0.010 |
Why?
|
| Fibrinolysis | 1 | 1998 | 322 | 0.010 |
Why?
|
| Hemoperfusion | 1 | 1997 | 14 | 0.010 |
Why?
|
| Delirium | 1 | 2009 | 1611 | 0.010 |
Why?
|
| Agglutination Tests | 1 | 1997 | 41 | 0.010 |
Why?
|
| Blood | 1 | 2000 | 596 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 1997 | 69 | 0.010 |
Why?
|
| Blood Component Removal | 1 | 1998 | 125 | 0.010 |
Why?
|
| Antidepressive Agents | 1 | 2009 | 2837 | 0.010 |
Why?
|
| Remission Induction | 1 | 2002 | 2384 | 0.010 |
Why?
|
| Antigens, Heterophile | 1 | 1997 | 69 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2012 | 4687 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1998 | 1581 | 0.010 |
Why?
|
| Cysts | 1 | 2002 | 678 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 4749 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 15067 | 0.010 |
Why?
|
| Models, Chemical | 1 | 1999 | 626 | 0.010 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 1998 | 426 | 0.010 |
Why?
|
| Cohort Studies | 3 | 2006 | 40545 | 0.010 |
Why?
|
| Lung | 1 | 2015 | 9858 | 0.010 |
Why?
|
| Antipsychotic Agents | 1 | 2009 | 3057 | 0.010 |
Why?
|
| Blood Urea Nitrogen | 1 | 1995 | 191 | 0.010 |
Why?
|
| Case-Control Studies | 2 | 2005 | 21733 | 0.010 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2000 | 652 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1999 | 2034 | 0.010 |
Why?
|
| Immunoglobulin A | 1 | 1978 | 995 | 0.010 |
Why?
|
| Prevalence | 2 | 2002 | 15211 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2007 | 5388 | 0.010 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 1995 | 286 | 0.010 |
Why?
|
| Species Specificity | 1 | 1999 | 2480 | 0.010 |
Why?
|
| Cholesterol, LDL | 1 | 2004 | 2354 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 1998 | 1035 | 0.010 |
Why?
|
| Endocardium | 1 | 1995 | 263 | 0.010 |
Why?
|
| Psychotic Disorders | 1 | 2009 | 3044 | 0.010 |
Why?
|
| Health Planning | 1 | 1996 | 237 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 2001 | 1360 | 0.010 |
Why?
|
| Myocardium | 2 | 1999 | 4775 | 0.010 |
Why?
|
| Microcirculation | 1 | 1999 | 1287 | 0.010 |
Why?
|
| Bacterial Infections | 2 | 1981 | 1400 | 0.010 |
Why?
|
| Eosinophils | 1 | 1998 | 954 | 0.010 |
Why?
|
| Advisory Committees | 1 | 1998 | 775 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 1999 | 847 | 0.010 |
Why?
|
| Government Regulation | 1 | 1998 | 522 | 0.010 |
Why?
|
| Cross-Sectional Studies | 2 | 2005 | 25032 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2008 | 12354 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1994 | 424 | 0.010 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 1998 | 1038 | 0.010 |
Why?
|
| New England | 1 | 1996 | 1022 | 0.010 |
Why?
|
| Pentamidine | 1 | 1992 | 45 | 0.010 |
Why?
|
| Substance-Related Disorders | 1 | 2009 | 4254 | 0.010 |
Why?
|
| Blood Coagulation | 1 | 1999 | 1127 | 0.010 |
Why?
|
| Genetic Engineering | 1 | 1998 | 950 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 1986 | 5021 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2004 | 3778 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 1998 | 2560 | 0.010 |
Why?
|
| Cross Infection | 1 | 1981 | 1416 | 0.010 |
Why?
|
| Lymphoid Tissue | 1 | 1993 | 454 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2000 | 2232 | 0.010 |
Why?
|
| Double-Blind Method | 4 | 1992 | 12020 | 0.010 |
Why?
|
| Cross Reactions | 1 | 1993 | 841 | 0.010 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1992 | 249 | 0.010 |
Why?
|
| United States Food and Drug Administration | 1 | 1998 | 1582 | 0.010 |
Why?
|
| Hypertension | 1 | 1990 | 8480 | 0.010 |
Why?
|
| Risk | 3 | 1992 | 9677 | 0.010 |
Why?
|
| Aerosols | 1 | 1992 | 623 | 0.010 |
Why?
|
| Contrast Media | 1 | 1983 | 5301 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 1999 | 2647 | 0.010 |
Why?
|
| Emergencies | 1 | 1996 | 1170 | 0.010 |
Why?
|
| Cryptococcus neoformans | 1 | 1989 | 119 | 0.010 |
Why?
|
| Candida | 1 | 1989 | 172 | 0.010 |
Why?
|
| Intraoperative Complications | 1 | 1995 | 1195 | 0.010 |
Why?
|
| Cell Division | 1 | 1995 | 4568 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 20121 | 0.000 |
Why?
|
| Heart Rate | 1 | 1999 | 4091 | 0.000 |
Why?
|
| Dendritic Cells | 1 | 1998 | 2720 | 0.000 |
Why?
|
| Leukocytes | 1 | 1995 | 2044 | 0.000 |
Why?
|
| Adjustment Disorders | 1 | 1987 | 70 | 0.000 |
Why?
|
| Pain | 1 | 2002 | 4987 | 0.000 |
Why?
|
| Insulin | 1 | 2001 | 6584 | 0.000 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 1986 | 91 | 0.000 |
Why?
|
| Immunity, Innate | 1 | 1998 | 2961 | 0.000 |
Why?
|
| Gene Expression | 1 | 1999 | 7793 | 0.000 |
Why?
|
| HLA-DR Antigens | 1 | 1987 | 645 | 0.000 |
Why?
|
| Patient Care Team | 1 | 1995 | 2528 | 0.000 |
Why?
|
| Kidney Tubules, Proximal | 1 | 1986 | 416 | 0.000 |
Why?
|
| Hepatitis B Vaccines | 1 | 1985 | 194 | 0.000 |
Why?
|
| Macrophages | 1 | 1998 | 5651 | 0.000 |
Why?
|
| Clone Cells | 1 | 1987 | 1692 | 0.000 |
Why?
|
| Arteries | 1 | 1987 | 1119 | 0.000 |
Why?
|
| Urography | 1 | 1983 | 313 | 0.000 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 1984 | 277 | 0.000 |
Why?
|
| Infectious Mononucleosis | 1 | 1981 | 131 | 0.000 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2004 | 11729 | 0.000 |
Why?
|
| Genetics, Population | 1 | 1984 | 933 | 0.000 |
Why?
|
| Pneumonia | 2 | 1981 | 2133 | 0.000 |
Why?
|
| Cystitis | 1 | 1979 | 93 | 0.000 |
Why?
|
| Evaluation Studies as Topic | 1 | 1981 | 1677 | 0.000 |
Why?
|
| Mice, Inbred Strains | 1 | 1981 | 1826 | 0.000 |
Why?
|
| Glycoproteins | 1 | 1986 | 2266 | 0.000 |
Why?
|
| Herpesvirus 4, Human | 1 | 1983 | 1041 | 0.000 |
Why?
|
| Psychotherapy | 1 | 1987 | 1640 | 0.000 |
Why?
|
| Urine | 1 | 1979 | 370 | 0.000 |
Why?
|
| Central Nervous System Diseases | 1 | 1981 | 518 | 0.000 |
Why?
|
| Sepsis | 2 | 1981 | 2593 | 0.000 |
Why?
|
| Simplexvirus | 1 | 1979 | 803 | 0.000 |
Why?
|
| Virus Diseases | 1 | 1981 | 711 | 0.000 |
Why?
|
| Polymorphism, Genetic | 1 | 1984 | 4326 | 0.000 |
Why?
|
| Immunotherapy | 1 | 1986 | 4437 | 0.000 |
Why?
|
| Fever | 1 | 1977 | 1616 | 0.000 |
Why?
|
| Cell Differentiation | 1 | 1986 | 11478 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 1981 | 7172 | 0.000 |
Why?
|
| Pneumonia, Viral | 1 | 1977 | 3241 | 0.000 |
Why?
|